Can a patient with chronic kidney disease and an upper respiratory tract infection safely take lagundi (Vitex negundo)?

Lagundi Should Be Avoided in CKD Patients

Patients with chronic kidney disease should not take lagundi (Vitex negundo) for upper respiratory tract infections due to the lack of safety data in CKD populations and the general nephrotoxic risk associated with herbal remedies in this vulnerable group.

Rationale Based on Guidelines

The KDIGO 2024 guidelines explicitly address this scenario through Practice Point 4.1.3, which directs clinicians to "review and limit the use of over-the-counter medicines and dietary or herbal remedies that may be harmful for people with CKD" 1. This recommendation stems from the fundamental principle that CKD patients are more susceptible to nephrotoxic effects of medications (Practice Point 4.1.1) 1.

Why Lagundi Poses Specific Risks in CKD

Lack of Renal Safety Data

• While lagundi demonstrates antitussive effects comparable to codeine and dextromethorphan in animal studies 2, no studies have evaluated its safety specifically in patients with impaired kidney function
• The LD50 exceeding 5000 mg/kg in mice with normal renal function 2 does not translate to safety in CKD, where drug metabolism and excretion are fundamentally altered

Herbal Medicine Nephrotoxicity Concerns

Chinese herbal medicine literature documents that herbal preparations can cause:

• Acute kidney injury
• Progressive CKD
• Fanconi syndrome
• Rhabdomyolysis 3

The nephrotoxic potential arises from multiple factors: intrinsic herb toxicity, contamination with heavy metals, incorrect processing, adulteration, and unpredictable drug-herb interactions 3. These risks are amplified in CKD patients who already have compromised renal reserve.

Unknown Renal Clearance Profile

The KDIGO guidelines emphasize considering GFR when dosing renally-cleared medications (Practice Point 4.2.1) 1. For lagundi, we have no data on:

• Whether active compounds are renally cleared
• If metabolites accumulate in reduced GFR states
• What dose adjustments (if any) would be appropriate

Safer Alternatives for URTI in CKD

Instead of lagundi, consider:

For symptomatic relief:

• Acetaminophen (dose-adjusted for severe CKD)
• Dextromethorphan for cough (standard dosing generally safe)
• Saline nasal irrigation
• Adequate hydration (unless fluid-restricted)

For bacterial superinfection (if indicated):

• Appropriately dose-adjusted antibiotics based on eGFR
• Monitor renal function during treatment (Practice Point 4.1.2) 1

Critical Monitoring If Patient Insists on Use

If a patient has already taken or insists on taking lagundi despite counseling:

1. Monitor eGFR and electrolytes closely within 48-72 hours and weekly during use 1
2. Watch for signs of AKI: decreased urine output, rising creatinine, electrolyte disturbances
3. Document the herbal use in the medical record for other providers 1
4. Perform thorough medication review to identify potential interactions with CKD medications (ACEi, ARBs, SGLT2i, diuretics) 1

Common Pitfall to Avoid

The most dangerous assumption is that "natural" or "traditional" means "safe in CKD." Patients often fail to report herbal medicine use to physicians, believing these preparations are harmless 3. Clinicians must specifically ask about herbal remedies during medication reconciliation, particularly in patients with unexplained AKI or progressive CKD 3.

The recent 2026 review acknowledges that despite traditional use and demonstrated anti-inflammatory properties, lagundi lacks "biomarker-based standardization" and "pharmacokinetic and toxicological evaluation" in vulnerable populations 4. Until such data exist, the risk-benefit ratio in CKD patients remains unacceptably unfavorable.